HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis

Celine Hernandez, … , Richard A. Friedman, Robert F. Schwabe


Cell death is a key driver of disease progression and carcinogenesis in chronic liver disease (CLD), highlighted by the well-established clinical correlation between hepatocellular death and risk for the development of cirrhosis and hepatocellular carcinoma (HCC). Moreover, hepatocellular death is sufficient to trigger fibrosis and HCC in mice. However, the pathways through which cell death drives CLD progression remain elusive. Here, we tested the hypothesis that high-mobility group box 1 (HMGB1), a damage-associated molecular pattern (DAMP) with key roles in acute liver injury, may link cell death to injury responses and hepatocarcinogenesis in CLD. While liver-specific HMGB1 deficiency did not significantly affect chronic injury responses such as fibrosis, regeneration, and inflammation, it inhibited ductular/progenitor cell expansion and hepatocyte metaplasia. HMGB1 promoted ductular expansion independently of active secretion in a nonautonomous fashion, consistent with its role as a DAMP. Liver-specific HMGB1 deficiency reduced HCC development in 3 mouse models of chronic injury but not in a model lacking chronic liver injury. As with CLD, HMGB1 ablation reduced the expression of progenitor and oncofetal markers, a key determinant of HCC aggressiveness, in tumors. In summary, HMGB1 links hepatocyte death to ductular reaction, progenitor signature, and hepatocarcinogenesis in CLD.

Find the latest version:
http://jci.me/91786/pdf
Introduction
Chronic liver disease (CLD) causes approximately 2 million deaths per year worldwide (1). In patients with CLD, liver cirrhosis and hepatocellular carcinoma (HCC) are the main contributors to morbidity and mortality and remain a significant clinical problem. HCC is the third leading cause of cancer mortality worldwide and the fastest rising cause of cancer mortality in the US (1, 2). Importantly, cirrhosis and HCC are strongly linked to CLD and chronic hepatocellular death (3). Accordingly, a large body of well-designed clinical studies has demonstrated a profoundly increased risk for the development of cirrhosis (4, 5) and HCC (6–8) as well as liver-specific mortality (9) in patients with persistently elevated levels of serum alanine aminotransferase (ALT) (reviewed in ref. 3). Interestingly, an increased risk for cirrhosis and HCC development in patients with high ALT is seen in different types of liver diseases, suggesting that cell death is a common risk factor for the progression (3). This concept is further supported by studies in mouse models with genetically induced chronic hepaticoblastoma death, such as mice with hepatocyte-specific deletion of Tak1, Nemo, or Mcl1, which spontaneously develop liver fibrosis and HCC (10–13), suggesting that chronic cell death is sufficient to initiate liver disease development and drive its progression. However, the mechanisms through which hepatocellular death promotes the development of liver cirrhosis and HCC remain poorly understood. Accordingly, there are currently no approved treatments that target cell death pathways to prevent the development of cirrhosis and HCC besides the treatment of the underlying disease.

The liver reacts to hepatocellular death with a wide range of injury responses that include inflammation, hepatocyte regeneration, fibrosis, and the appearance of “ductular reactions.” Ductular reactions contain cell populations, termed ductular or hepatic progenitor cells, which are thought to represent an alternative cellular source for the generation of hepatocytes that becomes relevant when hepatocytes lose their capacity to proliferate. While this concept has been developed on the basis of histopathological evidence in patients (14), the role of ductular cells in animal models remains a matter of debate (14). Despite strong expansion of ductular cells, lineage-tracing studies have shown that these cells do not significantly contribute to the generation of functional hepatocytes in the most commonly used models with a “progenitor response,” such as 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) and choline-deficient, ethionine-supplemented (CDE) diet–fed mice as well as Mdr2-knockout mice, most likely due to the insufficient suppression of hepatocyte proliferation (15–18). On the other hand, mouse and zebrafish models with severely suppressed hepatocyte proliferation have suggested an important role of ductular cells in hepatocyte formation (19–22). Moreover, human LGR5-positive duct-derived liver stem cells differentiate into hepatocytes in vitro and in vivo (23). Furthermore, hepatocytes can undergo reversible ductular metaplasia with expression of A6, CK19, osteopontin (OPN), and Sox9 (24, 25). Together, these studies indicate cellular plasticity...
as well as a context-dependent role for specific cell types in the chronically injured liver.

Although hepatic injury responses are geared toward repair and regeneration, they often become maladaptive in the long term, thereby contributing to the development of cirrhosis and HCC (3). In murine models, in which HCC arises in response to carcinogens or in the setting of chronic injury, tumors originate from hepatocytes and not from ductular cells (26, 27). In Diethyl-nitrosamine-induced (DEN-induced) HCC, tumor-forming cells express “progenitor markers” such as A6, CK19, H19, and EpCam (28), suggesting that hepatocyte metaplasia may be a first step in hepatocarcinogenesis. Moreover, a large body of clinical studies from the past decade has shown worse prognosis in HCC with alterations in liver regeneration may be restricted to some models with ductular reactions, suggesting that the observed minor alterations in liver regeneration may be restricted to some models with ductular reactions.

HMGBI is required but not sufficient for ductular reactions in the liver. We therefore next examined the possible role of HMGBI in the regulation of hepatocyte proliferation in the DDC diet model (Supplemental Figure 4D) or a single injection of CCl4 (Supplemental Figure 4E). We did not observe a role for HMGBI in the regulation of hepatocyte proliferation in either model, suggesting that the observed minor alterations in liver regeneration may be restricted to some models with ductular reactions.

HMGBI deletion did not affect serum ALT levels (Figure 1C). To test this hypothesis, we subjected mice with a liver-specific deletion of HMGBI (HmgbiΔhep) and HmgbiΔhep or HmgbiΔhep control mice to 3 different, well-characterized models of chronic liver injury, including the DDC diet model (42), Mdr2-knockout (Mdr2Δhep) mice (43), and TaktΔhep mice (10). Of note, we had previously shown that HmgbiΔhep mice showed efficient reduction of HMGBI in parenchymal cells but did not have any abnormalities in hepatic architecture, injury, fibrogenesis, or gene expression under baseline conditions (41, 44), suggesting that intracellular HMGBI does not play a key role in the maintenance of adult liver homeostasis. TaktΔhep, Mdr2Δhep, and DDC-treated mice had strong inflammation, fibrogenesis, and compensatory proliferation (Supplemental Figure 1–4; supplemental material available online with this article; https://doi.org/10.1172/JCI91786DS1) as well as robust ductular reactions, with characteristic increases in expression of the progenitor markers Cd133 and H19 and the oncofetal marker Afp, as well as increased cytokeratin staining (Figure 1, A–F). In contrast to our previous studies of acute liver injury, we only observed a minor to moderate role for HMGBI in the regulation of neutrophil recruitment, with a significant reduction in the DDC model, a borderline reduction in the Mdr2Δhep model, and no significant changes in the TaktΔhep model (Supplemental Figure 1, A, C, and E). Likewise, there were no significant differences in CD45+ cell recruitment in any of the 3 CLD models and no consistent alterations of inflammation, with markers such as Tnf and Ccl20 mRNA unaffected and Il6 mRNA upregulated in some models and downregulated in others (Supplemental Figure 1, B, D, and F). We observed no difference in macrophage recruitment in the Mdr2Δhep model, a trend toward reduced macrophage numbers in the DDC model, and reduced macrophage numbers in the Takt model in Hmgbi1Δhep mice (Supplemental Figure 2). Together, these data suggest that the regulation of sterile inflammation and neutrophil recruitment by HMGBI is mostly restricted to acute settings, when other inflammatory mediators such as chemokines and cytokines or gut-derived pathogen–associated molecular patterns (PAMPs) are not yet released. We also did not see a major role for HMGBI in the regulation of liver fibrosis in any of the 3 CLD models (Supplemental Figure 3, A–C). Likewise, we did not observe consistent alterations in proliferation, as determined by Ki67 or phosphorylated histone H3 (p–histone H3) IHC and mkI67 quantiative PCR (qPCR), with similar hepatocyte proliferation in HmgbiΔhep mice and HmgbiΔhep mice in the TaktΔhep model, increased proliferation in HmgbiΔhep mice in the Mdr2Δhep model, and decreased proliferation in HmgbiΔhep mice in the DDC diet model (Supplemental Figure 4, A–C). To further determine whether HMGBI is required for hepatocyte proliferation, we subjected Hmgbi1Δhep and HmgbiΔhep mice to a two-thirds partial hepatectomy (Supplemental Figure 4D) or a single injection of CCI4 (Supplemental Figure 4E). We did not observe a role for HMGBI in the regulation of hepatocyte proliferation in either model, suggesting that the observed minor alterations in liver regeneration may be restricted to some models with ductular reactions.
which Cre expression is controlled by the hepatocyte-specific thyroxine-binding globulin (TBG) promoter, as a hepatocyte-specific deletion approach (24, 41). This strategy resulted in a significant reduction in hepatic $Hmgb1$ mRNA levels and absent HMGB1 expression in hepatocytes but not in other liver cell types (Figure 2, A and B), thus affecting signals from hepatocytes to other cell types including ductular cells, but leaving HMGB1 within ductular cells intact.

Mdr2 KO mice with AAV8-TBG-Cre–mediated hepatocyte-specific HMGB1 deletion displayed a significant reduction of the progenitor markers $Cd133$ and $H19$ and decreased cytokeratin staining in comparison with mice injected with the AAV8-TBG-LacZ control virus (Figure 2, C and D). These finding were confirmed in the DDC model, in which we observed a reduction of $Cd133$ and $H19$ mRNA levels and cytokeratin staining in mice treated with AAV8-TBG-Cre versus mice that received the AAV8-TGB-LacZ virus (Figure 2, E and F). Together, our findings in the DDC and Mdr2 KO models exclude the possibility that the intracellular loss of HMGB1 within the biliary compartment simply

Passively released hepatocyte HMGB1 promotes ductular reactions via cell-extrinsic mechanisms and RAGE. As the deletion strategy via albumin-Cre mice not only ablates HMGB1 in hepatocytes but also in the biliary compartment (26, 41), we next sought to exclude the possibility that the lack of HMGB1 in ductular cells impaired their ability to expand. For this purpose, we deleted HMGB1 selectively in hepatocytes using AAV8-TBG-Cre, in which Cre expression is controlled by the hepatocyte-specific thyroxine-binding globulin (TBG) promoter, as a hepatocyte-specific deletion approach (24, 41). This strategy resulted in a significant reduction in hepatic $Hmgb1$ mRNA levels and absent HMGB1 expression in hepatocytes but not in other liver cell types (Figure 2, A and B), thus affecting signals from hepatocytes to other cell types including ductular cells, but leaving HMGB1 within ductular cells intact.

Mdr2 KO mice with AAV8-TBG-Cre–mediated hepatocyte-specific HMGB1 deletion displayed a significant reduction of the progenitor markers $Cd133$ and $H19$ and decreased cytokeratin staining in comparison with mice injected with the AAV8-TBG-LacZ control virus (Figure 2, C and D). These finding were confirmed in the DDC model, in which we observed a reduction of $Cd133$ and $H19$ mRNA levels and cytokeratin staining in mice treated with AAV8-TBG-Cre versus mice that received the AAV8-TGB-LacZ virus (Figure 2, E and F). Together, our findings in the DDC and Mdr2 KO models exclude the possibility that the intracellular loss of HMGB1 within the biliary compartment simply

1, B, D, and F), thus excluding the possibility that reduced ductular reactions in $Hmgb1^{Δhep}$ mice might have been caused by a decrease in liver injury. Similar to the above models, we also found inhibited ductular reactions in the methione-choline–deficient, ethionine-supplemented (MCDE) diet model (Supplemental Figure 6). Although there was a strong release of HMGB1, as seen by increased HMGB1 serum levels following treatment with the hepatotoxin CCl4, we did not observe ductular reactions in this model (Figure 1G). Together with our findings in the Tak1Δhep, Mdr2Δhep, DDC, and MCDE models, our data indicate that HMGB1 is required, but not sufficient, for the development of ductular reactions.

Figure 1. HMGB1 is required for ductular reactions. (A and B) Eight-week-old mice with hepatic deletion of HMGB1 ($Hmgb1^{Δhep}$, $n = 9$) had fewer cytokeratin-positive ductular cells (A) and lower expression of $Cd133$, $Afp$, and $H19$ mRNA but similar ALT levels (B) compared with $Hmgb1^{fl/fl}$ control mice ($n = 9$) in the Tak1Δhep model. (C and D) In the Mdr2Δhep model, 8-week-old $Hmgb1^{Δhep}$ mice ($n = 13$) had fewer cytokeratin-positive ductular cells (C) and lower expression of $Afp$ and $H19$ mRNA but similar ALT levels (D) compared with $Hmgb1^{fl/fl}$ control mice ($n = 10$). (E and F) After 3 weeks on a DDC diet, $Hmgb1^{Δhep}$ mice ($n = 9$) had fewer cytokeratin-positive ductular cells (E) and lower expression of $Afp$ and $H19$ mRNA but similar ALT levels (F) compared with $Hmgb1^{fl/fl}$ control mice ($n = 6$). (G) Untreated mice ($n = 4$) and mice treated with 6 injections of CCl4 ($n = 11$) had similar percentages of cytokeratin-positive cells. HMGB1 serum levels were determined by ELISA in mice that had received (n = 3) or not received (n = 6) 6 injections of CCl4. Data are expressed as the mean ± SEM. qPCR data are shown as the fold induction compared with normal liver. *$P < 0.05$, **$P < 0.01$, and ***$P < 0.001$, by unpaired, 2-tailed t test. Scale bars: 100 μm. CK, cytokeratin.
sive HMGB1 release from dying hepatocytes, rather than active secretion, is the dominant driver of ductular reactions in the settings we investigated.

HMGB1 binds to several receptors including RAGE (encoded by Ager), TLR4, and TLR9. We next determined which one of these three HMGB1 receptors was involved in promoting ductular reactions in vivo, using Ager-deficient (RageKO), Tlr4-deficient (Tlr4KO), and Tlr9-deficient (Tlr9KO) mice. We found strongly reduced ductular reactions with significantly decreased cytokeratin staining and reduced H19 and Afp mRNA expression, as well as a trend toward decreased Cd133 mRNA levels in livers from RageKO mice (Figure 4A). In contrast, Tlr4KO and Tlr9KO mice did not show impaired ductular reactions in the DDC diet model, as demonstrated by unaltered cytokeratin staining and unchanged or increased Cd133, H19, and Afp mRNA expression in Tlr4KO and Tlr9KO mice (Figure 4, B and C). As with HmgbbΔhep mice, we did not find alterations in liver injury in RageKO mice, thus excluding blocked ductular reactions, further supporting our hypothesis that hepatocellular HMGB1, acting as a DAMP, is essential for the induction of ductular reactions.

Extracellular HMGB1 can be released via passive leakage from dead cells (45) or via active secretion, the latter being mediated through acetylation of HMGB1 at multiple lysine residues (46). To determine whether passive release or active secretion of HMGB1 was driving ductular reactions, we inhibited HMGB1 secretion during DDC-induced liver injury using ethyl pyruvate, an established inhibitor of HMGB1 acetylation and secretion (47, 48). Although HMGB1 acetylation was completely suppressed by ethyl pyruvate (Figure 3, A and B), we did not observe significant effects on cytokeratin or A6 expression or on Cd133 or Afp mRNA levels and only a borderline significant reduction of H19 mRNA (Figure 3, C–E). Moreover, HMGB1 serum levels were not significantly decreased (Figure 3F), despite the observed loss of acetylated HMGB1. Together, these findings suggest that passive HMGB1 release from dying hepatocytes, rather than active secretion, is the dominant driver of ductular reactions in the settings we investigated.

HMGB1 binds to several receptors including RAGE (encoded by Ager), TLR4, and TLR9. We next determined which one of these three HMGB1 receptors was involved in promoting ductular reactions in vivo, using Ager-deficient (RageKO), Tlr4-deficient (Tlr4KO), and Tlr9-deficient (Tlr9KO) mice. We found strongly reduced ductular reactions with significantly decreased cytokeratin staining and reduced H19 and Afp mRNA expression, as well as a trend toward decreased Cd133 mRNA levels in livers from RageKO mice (Figure 4A). In contrast, Tlr4KO and Tlr9KO mice did not show impaired ductular reactions in the DDC diet model, as demonstrated by unaltered cytokeratin staining and unaltered or increased Cd133, H19, and Afp mRNA expression in Tlr4KO and Tlr9KO mice (Figure 4, B and C). As with HmgbbΔhep mice, we did not find alterations in liver injury in RageKO mice, thus excluding...
The Journal of Clinical Investigation

RESEARCH ARTICLE

Ours studies on acute liver injury, we found that disulfide HMGB1 was the most abundant form of HMGB1 in the chronically injured liver and that this form increased with the duration of liver injury (Figure 5A). More important, stimulation with these 2 forms of HMGB1, which have distinct bioactivities, revealed that only the disulfide form of HMGB1 upregulated \( \text{Cd133} \) mRNA in bipotential murine oval liver (BMOL) cells (Figure 5B), a well-characterized bipotential liver progenitor cell line (51). As YAP and Notch are well-established and powerful signals driving hepatocyte metaplasia toward a ductular phenotype in adult livers (24, 52) as well as hepatocarcinogenesis (53), we determined whether HMGB1 could act through these pathways. However, we found no difference in Notch target gene expression after treating BMOL cells with HMGB1, which was further confirmed by similar levels of Notch target genes in control and HMGB1-deleted mice in vivo in multiple models (Supplemental Figure 8). Following treatment of BMOL cells with HMGB1, we found that YAP target genes as the possibility that reduced ductular reactions were merely a consequence of less injury in the \( \text{Rage}^{-/} \) mice (Figure 4A).

Since we also observed small decreases in macrophages in HMGB1-deleted mice in some models (Supplemental Figure 2), we additionally sought to determine whether macrophages might be a cell population through which HMGB1 indirectly triggers progenitor responses. However, consistent with previous studies (49), we observed no decrease in ductular reactions following macrophage depletion (Supplemental Figure 7). Given these findings, we subsequently focused on the direct effect of HMGB1 on bipotential progenitor cells, with the goal of identifying the signals through which HMGB1 affects ductular reactions.

**Disulfide HMGB1 mediates effects on progenitor cells via Erk.** HMGB1 bioactivity is dependent on posttranslational modifications, with fully reduced HMGB1 promoting cell migration but not inflammation, whereas disulfide HMGB1 has cytokine-like proinflammatory activity (50). Similar to the findings from our previous studies on acute liver injury, we found that disulfide HMGB1 was the most abundant form of HMGB1 in the chronically injured liver and that this form increased with the duration of liver injury (Figure 5A). More important, stimulation with these 2 forms of HMGB1, which have distinct bioactivities, revealed that only the disulfide form of HMGB1 upregulated \( \text{Cd133} \), \( \text{Afp} \), and \( \text{H19} \) mRNA in mice treated with saline or ethyl pyruvate. (F) Serum HMGB1 levels in control and DDC-treated mice were determined by ELISA. Data are expressed as the mean ± SEM. qPCR data are expressed as the fold induction compared with normal liver. Statistical significance was determined by unpaired, 2-tailed \( t \) test. Scale bars: 100 \( \mu \)m.

**Figure 3. Active HMGB1 secretion does not drive ductular reactions.** (A) C57BL/6 male mice were pretreated with saline (n = 11) or ethyl pyruvate (n = 8), followed by a DDC diet for 3 weeks. (B) HMGB1 isoforms were determined by LC-MS/MS in plasma from untreated mice as well as in plasma from DDC diet–fed mice that received saline or ethyl pyruvate. (C and D) IHC showed similar expression levels of cytokeratin (C) and \( \text{A6} \) (D) in saline- and ethyl pyruvate–treated mice. (E) qPCR showed similar expression levels of \( \text{Cd133} \), \( \text{Afp} \), and \( \text{H19} \) mRNA in mice treated with saline or ethyl pyruvate. (F) Serum HMGB1 levels in control and DDC-treated mice were determined by ELISA. Data are expressed as the mean ± SEM. qPCR data are expressed as the fold induction compared with normal liver. Statistical significance was determined by unpaired, 2-tailed \( t \) test. Scale bars: 100 \( \mu \)m.
well as YAP reporter activity decreased (Supplemental Figure 9). In contrast, we observed a decrease in some YAP target genes in HMGB1-deleted mice in vivo (Supplemental Figure 9). As our experiment had not shown any direct effect of HMGB1 on YAP target genes in BMOL progenitor cells in vitro, and as we did not see a major role for hepatocyte YAP in ductular reactions after 3 weeks of DDC diet feeding (data not shown), we reasoned that the reduction of YAP target gene expression in HMGB1-deleted mice probably reflects the decrease in ductular cells (which are enriched in YAP and YAP target genes) rather than indicating a lack of HMGB1-induced YAP activation. Accordingly, when normalizing our qPCR results to the progenitor marker Cd133, the YAP target gene Ctgf was significantly (*P < 0.05) upregulated in HMGB1-deleted mice in the DDC model, and significantly (**P < 0.01) downregulated in the Tak1Δhep model where all others showed no significant differences between floxed and HMGB1-deleted mice (data not shown). Therefore, we sought to identify additional signals through which disulfide HMGB1 may affect ductular reactions. For this purpose, we performed a phospho-screen in BMOL cells treated with disulfide HMGB1. In this screen, we found that Erk phosphorylation and phosphorylation of its target CREB, but not other pathways, were strongly induced by disulfide HMGB1 (Figure 5C), which was further confirmed by Western blot analysis (Figure 5D, top). In contrast, fully reduced HMGB1 did not stimulate Erk phosphorylation (Figure 5D, bottom). Inhibition of Erk phosphorylation strongly decreased the expression of Cd133 mRNA in BMOL cells (Figure 5E), suggesting that this pathway mediates the effects of HMGB1 on progenitor cells. This finding is supported by previous studies that have described a key role of Erk in the regulation of CD133 (54, 55). Moreover, treatment with disulfide HMGB1 moderately but significantly promoted the proliferation of BMOL cells (Figure 5F), suggesting that HMGB1 contributes to progenitor expansion via this pathway. Indeed, we found that there was a reduction of p–histone H3 (Ser10)/Krt19–double-positive proliferating progenitor cells in HMGB1-deleted mice after 3 weeks of a DDC diet (Figure 5G). Consistent with our in vivo studies in knockout mice as well as a previously published study (56), we also found that inhibition of RAGE blunted HMGB1-induced Erk phosphorylation, whereas TLR4 or TLR9 blockade had no major effect (Figure 5H). In summary, our findings suggest that HMGB1-induced activation of RAGE triggers the proliferation and expansion of progenitor cells.

**HMGB1 promotes hepatocyte metaplasia and links chronic injury to HCC development.** Chronic liver injury may result in the development of HCC, the third leading cause of cancer mortality worldwide. Accordingly, chronic hepatocellular death strongly increases the risk for HCC development (6, 7). Moreover, the expression of progenitor and oncofetal genes is common in HCC and adversely affects prognosis (29–36). Consistent with previous studies (24, 25), we found via lineage tracing with AAV8-TBG-Cre that hepatocytes undergo ductular metaplasia, as seen by coexpression of the Cre reporter TdTom, demonstrating hepatocyte origin, and ductular markers A6, OPN, and Sox9 (Figure 6, A–D). In mice that had been fed a DDC diet for 3 weeks, A6-positive
hepatocytes constituted less than 10% of all A6-positive cells in the liver (Figure 6B). Of note, A6-positive metaplastic hepatocytes were reduced by 68% (P < 0.001) in HMGB1-deleted mice (Figure 6B). Likewise, we also detected a significant reduction of TdTom– and OPN– double-positive and TdTom– and Sox9– double-positive hepatocytes (Figure 6, C and D) as well as a significant reduction of Spp1 (encoding OPN) and Sox9 mRNA levels (Figure 6, E and F) in HMGB1-deleted mice. Together, these findings suggest that hepatocellular HMGB1 promotes ductular metaplasia of hepatocytes, but that this largely HMGB1-dependent response contributed only a small fraction to the overall ductular response at the time points that we studied. As A6–, CK19–, AFP–, H19–, Epcam– and Sox9–expressing cells may function as liver cancer progenitors (28), and given that HMGB1 had a major role in regulating the expression of these markers in the liver as well as the expression of A6 in hepatocytes in particular, we next tested the hypothesis that HMGB1 may provide a link between hepatocellular death and HCC development. For this purpose, we subjected Hmgb1fl/fl and Hmgb1Δhep mice to models of hepatocarcinogenesis that either incorporated or lacked chronic liver injury (Figure 7, A–G). To mimic the development of HCC in chronically injured, inflamed, and fibrotic livers in patients, we used the well-established combination of the
tumor numbers and size and a borderline significant reduction in liver/body weight ratios (Supplemental Figure 10, A–C). Likewise, we also observed a reduction in tumor formation in mice treated with DEN plus a DDC diet (Supplemental Figure 10, D and E), which triggers the development of HCC in the presence of chronic injury, ductular reactions, and progenitor marker expression (58). In contrast, when we subjected \( Hmgb1^{\Delta\text{hep}} \) or \( Hmgb1^{\text{fl/fl}} \) control mice to DEN-induced hepatocarcinogenesis, a purely genotoxic model without chronic liver injury or strong HMGB1 release (Figure 7D), we observed abundant tumors in both groups of mice, without significant differences in tumor number, size, or liver/body weight ratio (Figure 7, E–G). The finding that cell death was required to reveal effects of hepatic HMGB1 strongly suggests that HMGB1 carcinogen DEN with chronic injection of the hepatotoxin CCl\(_4\) or with the above-described DDC diet model (57, 58). The DEN plus CCl\(_4\) model resulted in a significantly increased release of HMGB1 in comparison with the DEN-only model (Figure 7D). In the DEN plus CCl\(_4\) model, we found a significant reduction of HCC development, as determined by tumor numbers and liver/body weight ratios, and a borderline significant reduction (\( P = 0.06 \)) in tumor size (Figure 7, A–C). To further confirm the contribution of HMGB1 to injury-driven hepatocarcinogenesis, we next tested its role in mice with hepatocyte-specific deletion of \( Takt1 \). In this model, mice spontaneously develop HCC (10, 59) as a result of chronic cell death, without the need for injection of carcinogens. As with the DEN plus CCl\(_4\) model, we observed a significant reduction in tumor numbers and size and a borderline significant reduction in liver/body weight ratios (Supplemental Figure 10, A–C). Likewise, we also observed a reduction in tumor formation in mice treated with DEN plus a DDC diet (Supplemental Figure 10, D and E), which triggers the development of HCC in the presence of chronic injury, ductular reactions, and progenitor marker expression (58). In contrast, when we subjected \( Hmgb1^{\Delta\text{hep}} \) or \( Hmgb1^{\text{fl/fl}} \) control mice to DEN-induced hepatocarcinogenesis, a purely genotoxic model without chronic liver injury or strong HMGB1 release (Figure 7D), we observed abundant tumors in both groups of mice, without significant differences in tumor number, size, or liver/body weight ratio (Figure 7, E–G). The finding that cell death was required to reveal effects of hepatic HMGB1 strongly suggests that HMGB1 promotes ductular metaplasia of hepatocytes. (A) Seven-week-old HMGB1 WT mice (\( Hmgb1^{\text{WT/WT}}, n = 12 \)) or mice with floxed HMGB1 alleles (\( Hmgb1^{\text{fl/fl}}, n = 8 \)), both expressing TdTom, were infected with AAV8-TBG-Cre (i.v., \( 10^{11} \) genome copies), followed by a three-week-long DDC diet, one week after AAV infection. (B–D) Hepatocyte metaplasia was compared using dual immunofluorescence staining for A6 and TdTom (B), OPN and TdTom (C), or Sox9 and TdTom (D). \( Hmgb1^{\text{fl/fl}} \) mice showed a reduction in cells double-positive for A6 and TdTom compared with \( Hmgb1^{\text{WT/WT}} \) mice as well as of the percentage of A6– and TdTom–double-positive cells among all A6-positive cells (B). \( Hmgb1^{\Delta\text{hep}} \) mice showed a reduction of OPN– and TdTom–double-positive cells (C) as well as a reduction of Sox9– and TdTom–double-positive cells (D) when compared with \( Hmgb1^{\text{WT/WT}} \) mice. (E and F) qPCR showed decreased expression of OPN (encoded by \( Spp1 \)) and Sox9 mRNA in DDC diet–treated \( Hmgb1^{\Delta\text{hep}} \) mice. qPCR data are shown as the fold induction compared with normal liver. Data are expressed as the mean ± SEM. \( *P < 0.05 \), \( **P < 0.01 \), and \( ***P < 0.001 \), by unpaired, 2-tailed \( t \) test. Scale bar: 100 \( \mu \text{m} \).
expression in tumors from Hmgb1Δhep and Hmgb1fl/fl mice (Figure 8, A–C, and Supplemental Figure 11, A–C). Likewise, we did not find a role for HMGB1 in the recruitment of neutrophils (Figure 8D), a cell population that contributes to the development of liver cancer (60) and whose numbers positively correlate with worse prognosis in HCC (61, 62). Given that we observed a moderate role for HMGB1 in neutrophil recruitment in earlier stages of injury (Supplemental Figure 1, A–C), and since HMGB1 might not only contribute to neutrophil recruitment but also to neutrophil activation, we additionally performed functional experiments with mice deficient for neutrophil elastase (encoded by Elane), which acted as a DAMP and excludes the possibility that the lack of intracellular HMGB1 might have simply impaired the ability of tumor-initiating cells to form tumors.

**HMGB1 controls the progenitor signature but not fibrosis, inflammation, or proliferation in HCC.** To better understand the mechanisms through which HMGB1 promotes hepatocarcinogenesis in the injured liver, we focused on tumor-promoting injury responses. Similar to our findings in chronic injury models, we did not observe differences in proliferation, fibrosis, or inflammation, as demonstrated by similar levels of Ki67+, Picrosirius red, CD45+, and F4/80+ staining, as well as similar levels of inflammatory gene expression in tumors from Hmgb1Δhep and Hmgb1fl/fl mice (Figure 8, A–C, and Supplemental Figure 11, A–C). Likewise, we did not find a role for HMGB1 in the recruitment of neutrophils (Figure 8D), a cell population that contributes to the development of liver cancer (60) and whose numbers positively correlate with worse prognosis in HCC (61, 62). Given that we observed a moderate role for HMGB1 in neutrophil recruitment in earlier stages of injury (Supplemental Figure 1, A–C), and since HMGB1 might not only contribute to neutrophil recruitment but also to neutrophil activation, we additionally performed functional experiments with mice deficient for neutrophil elastase (encoded by Elane), which
mediated modulation of YAP and TAZ. To better understand the influence of HMGB1 on hepatocarcinogenesis and follow up on the above-described finding that HMGB1 promotes the ductular metaplasia of hepatocytes (Figure 6), we performed RNA-seq in tumors from \( \text{Hmgb1}\Delta \) hep and \( \text{Hmgb1}\text{fl/fl} \) mice treated with DEN plus CCl4. Unsupervised clustering of differentially expressed genes showed that tumors from \( \text{Hmgb1}\Delta \) hep mice clustered closer with normal liver than tumors from \( \text{Hmgb1}\text{fl/fl} \) mice (Figure 9A and Supplemental Table 1). Accordingly, 675 of 848 genes (79.6%) in tumors from \( \text{Hmgb1}\Delta \) hep mice had expression levels in the direction of normal liver (\( P < 2.2 \times 10^{-16} \)). A more mature phenotype of tumors from \( \text{Hmgb1}\Delta \) hep mice was further supported by the strong reduction in the oncofetal and progenitor markers \( \text{Cd133} \), \( \text{H19} \), and \( \text{Afp} \) in \( \text{Hmgb1}\Delta \) hep tumors in our RNA-seq data (Supplemental Table 1), which was confirmed by qPCR and immunohistochemical AFP and A6 staining (Figure 9, B–D). These findings are consistent with clinical findings, in which HMGB1 serum levels were increased in HCC patients and strongly correlated with AFP levels (64). As we had previously shown that A6-positive tumor cells within HCC are derived from hepatocytes (26), our present find-

Figure 8. HMGB1 does not regulate fibrosis, proliferation, or inflammation in HCC. (A–D) Tumors from \( \text{Hmgb1}\text{fl/fl} \) mice (\( n = 12 \)) and \( \text{Hmgb1}\Delta \) hep mice (\( n = 12 \)) treated with DEN plus 15 injections of CCl4 were analyzed by IHC and qPCR to determine proliferation (A), fibrosis (B), infiltrating CD45+ leukocytes, (C) and Ly6B+ neutrophils (D). (E) Hepatocarcinogenesis was induced in male WT (\( n = 10 \)) and neutrophil elastase-deficient (\( \text{Elane}\text{KO} \), \( n = 11 \)) mice using the combination of DEN and 15 injections of CCl4, followed by quantification of tumor numbers, size, and liver/body weight ratios. Data are expressed as the mean ± SEM. qPCR data are shown as the fold induction compared with normal liver. Statistical significance was determined by unpaired, 2-tailed \( t \) test. Scale bars: 100 μm.
nificant progenitor response, despite increased HMGB1 release. Together, these findings indicate that HMGB1 release is necessary but not sufficient to trigger an effective progenitor response in the liver. Our data from two injury models with AAV8-TBG-Cre-mediated hepatocyte-specific HMGB1 deletion also exclude the possibility that the lack of intracellular HMGB1 in the ductular compartment may have impaired their ability to respond to injury. Of note, the majority of A6-positive ductular cells were not derived from hepatocytes, indicating that hepatocyte-derived HMGB1 acts in a nonautonomous fashion on other cell types to drive ductular reactions. As such, we found that HMGB1 was able to trigger Erk activation and proliferation in BMOL progenitor cells in vitro, suggesting that the effects of HMGB1 on ductular reactions in the injured liver are direct. In conjunction with our finding that HMGB1-deleted mice had a lower amount of Ki67-positive progenitor ductular cells and an extensive phospho-pathway screen in HMGB1-treated BMOL progenitor cells, these data suggest that HMGB1 stimulates ductular expansion predominantly via Erk activation and proliferation. Our in vivo data in Tlr4KO, Tlr9KO, and RageKO mice and in vitro studies with RAGE, TLR4, and TLR9 inhibitors demonstrate that HMGB1 contributes to the ductular reaction via RAGE. Using liposomal clodronate, we excluded macrophages as a target that may indirectly mediate progenitor responses, but we cannot completely rule out the possibility that HMGB1 may additionally affect progenitors through indirect mechanisms that involve other cell types. Our studies using ethyl pyruvate also showed that active secretion of HMGB1 is not a key driver in DDC-induced ductular reactions, further emphasizing the key role of HMGB1 released from dying cells in this setting. These data are further supported by our finding that secreted, i.e., the acetylated form of disulfide HMGB1 was less abundant than

ings demonstrate that HMGB1 is a key pathway driving metaplasia and the progenitor signature in hepatocytes and hepatocyte-derived tumor cells. Notably, the presence of progenitor markers is one the most characteristic features of dedifferentiated HCC, and a large body of literature has demonstrated a positive correlation with worse clinical outcomes (29–36). As we had identified a key role for the HMGB1 receptor RAGE in driving ductular reactions in CLD, we next investigated the role of RAGE in HCC development and observed a significant reduction in tumor development in RageKO mice in the DEN plus CCl4 model, as demonstrated by a reduction of tumor numbers, size, and liver/body weight ratios (Supplemental Figure 13).

**Discussion**

Cell death is a key component of CLD and considered an important driver of progression to fibrosis, cirrhosis, and HCC (3). Although DAMPs, including HMGB1, contribute to sterile inflammation in the setting of acute liver injury (38, 41, 65), their role in other injury responses and contribution to CLD remain enigmatic. Our data implicate HMGB1 as an important hepatocyte DAMP that regulates specific cell death responses in the chronically injured liver. Our findings suggest that the main effect of HMGB1 in CLD is the promotion of ductular reactions, whereas other injury responses such as regeneration, inflammation, or fibrosis are not significantly affected. Given that we observed a strong but incomplete suppression of ductular reactions in Hmgb1Δhep mice, HMGB1 represents a key contributor for the efficient execution of this response but is not the only driver. This is consistent with findings that pathways such as β-catenin (66, 67), CCN1 (68), and FGF signaling (69) also promote ductular reactions in the liver. Moreover, in our study, CCl4-induced liver injury did not trigger a significant progenitor response, despite increased HMGB1 release. Together, these findings indicate that HMGB1 release is necessary but not sufficient to trigger an effective progenitor response in the liver. Our data from two injury models with AAV8-TBG-Cre-mediated hepatocyte-specific HMGB1 deletion also exclude the possibility that the lack of intracellular HMGB1 in the ductular compartment may have impaired their ability to respond to injury. Of note, the majority of A6-positive ductular cells were not derived from hepatocytes, indicating that hepatocyte-derived HMGB1 acts in a nonautonomous fashion on other cell types to drive ductular reactions. As such, we found that HMGB1 was able to trigger Erk activation and proliferation in BMOL progenitor cells in vitro, suggesting that the effects of HMGB1 on ductular reactions in the injured liver are direct. In conjunction with our finding that HMGB1-deleted mice had a lower amount of Ki67-positive progenitor ductular cells and an extensive phospho-pathway screen in HMGB1-treated BMOL progenitor cells, these data suggest that HMGB1 stimulates ductular expansion predominantly via Erk activation and proliferation. Our in vivo data in Tlr4KO, Tlr9KO, and RageKO mice and in vitro studies with RAGE, TLR4, and TLR9 inhibitors demonstrate that HMGB1 contributes to the ductular reaction via RAGE. Using liposomal clodronate, we excluded macrophages as a target that may indirectly mediate progenitor responses, but we cannot completely rule out the possibility that HMGB1 may additionally affect progenitors through indirect mechanisms that involve other cell types. Our studies using ethyl pyruvate also showed that active secretion of HMGB1 is not a key driver in DDC-induced ductular reactions, further emphasizing the key role of HMGB1 released from dying cells in this setting. These data are further supported by our finding that secreted, i.e., the acetylated form of disulfide HMGB1 was less abundant than

**Figure 9. HMGB1 promotes tumor dedifferentiation and the progenitor signature.** Tumors from Hmgb1fl/fl (n = 6) and Hmgb1Δhep (n = 6) mice treated with DEN plus 15 injections of CCl4, as well as healthy control livers (n = 3) were subjected to RNA-seq. (A) Heatmap shows genes in the most relevant pathways, as described in Methods. (B) Expression of Cd133, Afp, and H19 was confirmed by qPCR. (C and D) AFP (C) and A6 (D) expression were determined by IHC in Hmgb1fl/fl (n = 7–12) and Hmgb1Δhep (n = 10–12) tumors. Data are expressed as the mean ± SEM. qPCR data are shown as the fold induction compared with normal liver. *P < 0.05 and **P < 0.01, by unpaired, 2-tailed t test. Scale bars: 100 μm.
the nonacetylated form in DDC-mediated injury. However, it is conceivable that secretion of acetylated HMGB1 is more abundant and may drive ductular reactions in other settings.

Although hepatocytes are the primary source for liver regeneration in multiple mouse models including those involving DDC or CDE diets, CCl\textsubscript{4} injection, and partial hepatectomy (15, 16), these models do not achieve efficient suppression of hepatocyte proliferation and may not be ideal to test the contribution of ductular cells (14). Recent studies in novel mouse models (21, 22) as well as data from zebrafish (19, 20) demonstrated a key contribution of the ductular compartment to liver regeneration in settings in which hepatocyte proliferation is efficiently blocked. Accordingly, Lgr5-positive liver stem cells can generate hepatocytes in vitro and in vivo (23). However, it remains unclear whether HMGB1-mediated ductular cell expansion contributes to hepatocyte generation from this source and whether this may represent a regenerative mechanism in the setting of severe injury. Further studies of HMGB1 in models with efficient suppression of hepatocyte proliferation in combination with positive lineage tracing of ductular cells will be required to answer this question.

The second key finding of our study was the reduction of HMGB1 in mice with liver-specific HMGB1 deletion. Hepatocellular death is a risk factor for HCC development (3, 6, 7), and our data suggest that HMGB1 may provide a molecular link between cell death and HCC development in the chronically injured liver. This hypothesis is supported by our finding that HMGB1 did not significantly affect HCC development in a mouse model that lacks chronic cell death and subsequent HMGB1 release, whereas HCC development was blocked in 3 different HCC models with chronic cell death. These data not only demonstrate the key role of HMGB1 as a tumor-promoting DAMP in the setting of chronic injury, but also exclude the possibility that reduced HCC development was caused by the loss of intracellular HMGB1. As with our data on HMGB1 in ductular reactions, we found that RAGE was the most likely candidate receptor through which HMGB1 mediated its effect on hepatocarcinogenesis. This finding is consistent with those of a published study using the Mdr2\textsuperscript{−/−} model, in which Rage\textsuperscript{−/−} mice developed less HCC (56). Together, our findings suggest that the HMGB1/RAGE signaling axis provides a molecular link between cell death and hepatocarcinogenesis and is likely a key component of maladaptive wound-healing responses, which are geared toward repairing the injured liver but become maladaptive and increase the risk for HCC development in the long term. Importantly, the gene expression tumors from Hmgbt\textsuperscript{−/−}\textsubscript{fl/fl} mice were more similar to normal liver, and expressed lower levels of progenitor and oncofetal markers than tumors from Hmgbt\textsuperscript{−/−}\textsubscript{fl/fl} mice. High expression of these markers, reflecting poorly differentiated and stem cell–enriched tumors, has been correlated with poor clinical prognosis in a wide body of literature (29–36). Notably, serum HMGB1 levels are strongly increased in HCC patients and correlate with AFP levels as well as tumor size (64). Progenitor cells do not give rise to HCC in a large number of murine models, including the DEN plus CCl\textsubscript{4}, and DEN plus DDC models used in the current study (26, 27). As CCl\textsubscript{4}-induced liver injury is not associated with the development of ductular reactions, it is likely that HMGB1 induces protumorigenic signals (e.g., in the DEN plus CCl\textsubscript{4} model) directly in preneoplastic or tumor cells. Given the findings of a study showing that tumor-forming cells, which are hepatocyte derived in DEN-induced HCC, express progenitor markers such as A6, CK19, H19, Epcam, and Sox9 (28), it is conceivable that HMGB1-mediated ductular metaplasia could increase the tumor-initiating capacity of hepatocytes. Future studies using metaplastic hepatocyte tracing are needed to determine whether these cells are more tumorigenic and how deletion of the HMGB1/RAGE signaling axis affects tumor formation from this cellular source. In addition, HMGB1-mediated increases of progenitor markers within already established tumors could promote more aggressive tumor behavior, as demonstrated by the strong clinical correlation between the progenitor signature and clinical outcomes (29–36). Further studies are required to determine these different possibilities and to identify downstream signals through which HMGB1 contributes to hepatocarcinogenesis and tumor dedifferentiation. In contrast to a recent study that reported HMGB1-regulated transcriptional activation of YAP in HCC (70), we did not observe a role for HMGB1 in regulating YAP or TAZ mRNA or protein expression or the expression of YAP target genes in HCC. This is consistent with our previous studies in normal liver (44), in which microarray analysis did not reveal differences in the expression of Yap1, Wwtr1 (encoding TAZ), or the YAP target genes Ankrd1, Ctgf, Cyr61, or Spp1, and is consistent with the fact that YAP and TAZ activity are predominantly regulated through posttranslational modification and protein stability rather than through transcription. Regardless of the underlying mechanism by which HMGB1 promotes hepatocarcinogenesis, our data suggest that interfering with this pathway could delay HCC development in patients with CLD. Glycyrrhizin, a phytochemical that inhibits HMGB1 (71), is widely used for the treatment of liver disease in Asia, and there are indications that glycyrrhizin can reduce HCC development in certain patient subsets (72).

Our study also demonstrates that hepatocellular HMGB1 is not a “master” DAMP that regulates all wound-healing responses in the chronically injured liver. As such, we did not observe an important contribution of HMGB1 in cell death responses such as fibrogenesis, inflammation, and proliferation. However, we observed a reduction of neutrophil recruitment in some models and a trend toward reduced neutrophil recruitment in other models in early stages of chronic liver injury. These findings are consistent with our previous findings on HMGB1/RAGE-mediated neutrophil recruitment in acute injury (41) but suggest that other pathways are more potent regulators of neutrophil recruitment in CLD. In contrast to a recent study on the role of HMGB1 in liver regeneration following acetaminophen intoxication (73), we did not observe a major role for HMGB1 in liver regeneration, except for a reduction of proliferation in the DDC diet model. In addition to using a different model, Tirone et al. (73) administered recombinant nonoxidizable HMGB1, whereas we deleted HMGB1. Thus, it is likely that the effects of HMGB1 on liver regeneration are model and redox dependent. Our results on the role of HMGB1 in liver fibrosis also differ from those of a recently published study (74). Our findings were based on 3 different models (Tak1\textsuperscript{−/−}, Mdr2\textsuperscript{−/−}, and the DDC diet) and were additionally confirmed in the MCDF diet model and in CCl\textsubscript{4}-induced liver injury (data not shown). Moreover, liver-specific deletion of HMGB1 in mice with hepatic autophagy deficiency due to loss of ATG7 also
did not show alteration in liver fibrosis (75), further confirming our data. Together, these findings suggest that additional cell death pathways, possibly mediated by other DAMPs or apoptotic bodies, might link cell death and fibrosis in the chronically injured liver. In summary, our findings suggest that DAMPs mediate cell death responses in a context-specific and a cell type-specific manner and that multiple branches of the hepatic wound-healing response are most likely regulated through a variety of DAMPs rather than a single master DAMP.

Methods

Mice. Mice were maintained on a 12-hour dark/12-hour light cycle with ad libitum access to food and water. Hmgb1fl/fl mice (41, 44) were backcrossed with C57BL/6 background at least 5 times. C57BL/6 mice, albumin-Cre mice, the Cre reporter line TdTomato (stock no. 007914), Tlr4−/− mice (stock no. 007227), and Tak1fl/fl mice (stock no. 011039) were purchased from The Jackson Laboratory. Rage−/− mice were a gift of Ann-Marie Schmidt (New York University, New York, New York, USA). Mdr2−/− mice (on a FVB background) were obtained from Detlef Schuppan (University of Mainz, Mainz, Germany). For conditional knockout of Hmgb1 in the Tak1fl/fl model, Tak1fl/fl or Tak1−/− and Hmgb1fl/fl double-floxed mice expressing albumin-Cre were bred with floxed or double-floxed mice negative for albumin-Cre. For conditional deletion of Hmgb1 in Mdr2−/− mice, Hmgb1fl/fl mice expressing albumin-Cre were backcrossed 3 times with Mdr2−/−, followed by further interbreeding of the F3 generation.

HCC induction and evaluation. HCC was induced by a combination of DEN and CCl4 injections for the majority of experiments. Male offspring were injected with a single i.p. dose of DEN (25 mg/kg body weight, MilliporeSigma) on postpartum day 15. Four weeks later, mice were treated with 15 weekly i.p. injections of CCl4 (0.5 ml/g body weight, dissolved in corn oil at a ratio of 1:3, MilliporeSigma) and sacrificed 8–10 weeks after the last CCl4 injection. Some mice were fed a DDC diet for 4 months starting 4 weeks after receiving DEN and CCl4 injections for the majority of experiments. As a pure genotoxic model of HCC, some mice were treated with a single dose of DEN (25 mg/kg, on postpartum day 15) and sacrificed 11 months later. For quantification, HCC tumor numbers and the largest tumor sizes were determined by counting the number of visible tumors (exceeding 1 mm in diameter) and measuring the size of the largest tumor with a caliper, respectively (57).

Chronic liver injury models. Chronic liver injury was induced in 8- to 10-week-old male mice by feeding them a 0.1% DDC diet or an MCD diet supplemented with 0.15% ethionine (for 3 weeks and 2 weeks, respectively). For selective deletion of HMGBl in hepatocytes, Hmgb1fl/fl mice were injected i.v. with 1010 genome copies of AAV8-TBG-Cre or AAV8-TBG-LacZ (58) on day 15 postpartum (for the Mdr2−/− mice) or 6 weeks postpartum (for all other mice). For some experiments, mice fed a DDC diet were treated with ethyl pyruvate (40 mg/kg, i.p., given twice weekly throughout the entire time mice were fed DDC diet). For some experiments, mice fed a DDC diet were treated with liposomal clodronate or control liposomes (4 μl/g body weight, i.p., both from Liposoma), on days 4, 8, and 12 after starting the diet.

Partial hepatectomy and acute CCl4-induced liver injury. A two-thirds partial hepatectomy was performed as described previously (76). Acute liver injury and subsequent hepatocyte proliferation were induced by a single i.p. injection of CCl4 (0.5 ml/kg body weight, dissolved in corn oil at a ratio of 1:3).

Hepatocyte tracing. To trace hepatocytes and determine whether HMGBl deletion alters the presence of hepatocyte-derived ductular cells, mice that were either WT or Hmgb1fl/fl and also expressed the Cre reporter TdTomato were injected with 1011 genome copies of AAVR-TBG-Cre. One week later, mice were fed a DDC diet for 3 weeks. Subsequently, ductular metaplasia of hepatocytes was determined in liver sections by identification of TdTom- positive cells coexpressing A6, Sox9, or OPN.

IHC and immunofluorescence. Paraffin-embedded or frozen liver sections were stained with primary antibodies directed against A6 (77) (a gift of Valentina Factor, NIH); AFP (ProteinTech, catalog 14550-1-AP); pan-cytokeratin (Dako, catalog Z0622); cytokeratin 19 (Developmental Studies Hybridoma Bank [DSHB] at the University of Iowa, Iowa City, IA); Ki67 (Abcam, catalog ab16667); Ly-6B.2 (AbD Serotec, clone MCA771G); F4/80 (AbD Serotec, clone C3H-10L, catalog MCA497R); CD3 (Thermo Fisher Scientific, catalog RM-9107-S0); CD45 (BD Pharmingen, catalog 550539); YAP (Abcam, catalog ab205270); p–histone H3 (Ser10) (Santa Cruz Biotechnology, catalog sc-8656); Sox9 (MilliporeSigma, catalog AB5535); and OPN (R&D Systems, catalog AF808). Detection was performed using either a fluorescent secondary antibody with various fluorescent conjugates (all from Thermo Fisher Scientific; chicken anti-goat, A21467; donkey anti-rabbit, A21206 or A21207; donkey anti-rat, A21208) or the Vectastain ABC HRP Kit (Vector Laboratories) with DAB or VIP substrate, followed by counterstaining with either DAPI (Thermo Fisher Scientific, D1306) or hematoxylin or methyl green. Fluorescence images were taken on a Nikon A1 confocal laser microscope. Nonfluorescence images were taken on an Olympus microscope coupled to a Retiga camera (Q Imaging). Morphometric quantification of immunohistochemical staining was done using Adobe Photoshop, with the exception of quantification of hepatocyte and progenitor cell proliferation, which was done using Fiji software. For quantification of hepatocyte proliferation, size and circularity thresholds were set so that nuclei of nonhepatocyte cells were not counted. For some experiments, IHC was performed with both fluorescence and a VIP substrate, with fluorescence images displayed as representative images and quantification done using VIP staining.

Western blot analysis and phospho-kinase screening. Western blotting for the detection of p–Erk was done using a primary mouse antibody against YAP/TAZ (Cell Signaling Technology, catalog 8418). Membranes were reprobed with HRP-conjugated GAPDH (MilliporeSigma, catalog G9295). After detection of p–Erk (Thr202/Tyr204) (Cell Signaling Technology, catalog 9106), membranes were stripped and relabeled with a rabbit antibody against Erk (Cell Signaling Technology, catalog 4695). Phospho-kinase screening was performed using a phospho-kinase array (R&D Systems, ARY003B) according to the manufacturer’s instructions.

RNA isolation and qPCR. RNA was isolated from cells and tissues by column purification and on-column DNase treatment (Roche Diagnostics). Following reverse transcription, qPCR was performed using primer-probe pairs (Applied Biosystems) and relative standard curves as described previously (57).

Analysis of HMGBl by electrospray ionization liquid chromatography tandem mass spectrometry. Posttranslational modifications of HMGBl were detected in mouse plasma with liquid chromatography tandem mass spectrometry.
mass spectrometry (LC-MS/MS) using an AB Sciex QTRAP 5500 or an AB Sciex TripleTOF 5600 equipped with a NanoSpray II source by in-line LC and an U3000 HPLC System connected to a 180 μm × 20 mm nanoACQUITY UPLC C18 trap column and a 75 μm × 15 cm nanoACQUITY UPLC BEH130 C18 column (Waters) using previously described conditions (41, 78).

RNA-seq and bioinformatics. RNA (RNA integrity number [RIN] >8, as determined by Bioanalyzer 2100, Agilent Technologies) from normal liver HCC (n = 3) or HCC from Hmgb1Δ/Δ (n = 6) or Hmgb1Δ/Δ (n = 6) mice was used to construct libraries with the Illumina TruSeq RNA Preparation Kit according to the manufacturer’s instructions. Thirty million 100-bp single-end sequencing was performed on the Illumina 2500 at the JP Sulzberger Columbia Genome Center (New York, New York, USA). These data were deposited in the Gene Expression Omnibus database (GEO GSE89689). Differential expression was determined between both Hmgb1Δ/Δ HCC and Hmgb1Δ/Δ HCC and between Hmgb1Δ/Δ HCC and normal liver. Counts were normalized with the trimmed mean of M values method (TMM) (79). Differential expression was estimated using weighted Limma-Voom, with a significance cutoff of the Benjamini-Hochberg FDR of 0.05 or less, an absolute log, fold change of 0.6 or greater, and restriction to the 12 most significant pathways as determined by iPathwayGuide, plus the progenitor and oncofetal genes Afp, H19, and Prom1. Both identification and calculation were performed in R. TMM-normalized counts of these genes were transformed by log2(counts + 0.5) centered, clustered with average linkage clustering using cluster 3.0, and displayed with Java TreeView (http://jtreeview.sourceforge.net/). The statistical significance of genes from Hmgb1Δ/Δ HCC that showed expression in the direction of normal liver versus those that did not was calculated with the binomial test.

Cell lines and cell culture experiments. BMOL cells (provided by George Yeoh, University of Western Australia, Perth, Australia) (51) were seeded in 12-well or 24-well plates in William’s E medium (Thermo Fisher Scientific), supplemented with 10% FBS (Gemini), recombinant mouse EGF (10 ng/ml, Thermo Fisher Scientific), and human recombinant insulin (10 μg/ml, Thermo Fisher Scientific). Cells were treated next day with either disulfide or a fully reduced form of HMGB1 (80) for the indicated durations (Figure 5, B–F and H; Supplemental Figure 8D; and Supplemental Figures 9, D and E). Cells were then lysed for gene expression and Western blot analysis. When indicated, the cells were pretreated for 30 minutes with the MEK inhibitor UO126 (MilliporeSigma). To determine proliferation, cells were grown in media containing 1% FBS and growth factors, followed by addition of HMGB1 and an MTT assay (Invitrogen, Thermo Fisher Scientific). For some experiments, cells were pretreated with anti-RAGE (5 μg/ml, Santa Cruz Biotechnology, catalog sc-365154) or an isotype control (5 μg/ml, Santa Cruz Biotechnology, sc-3877); anti-TLR4 (5 μg/ml, InvivoGen, catalog mab-mt1r4md2) or an isotype control (5 μg/ml, InvivoGen, catalog mabh2a-clr1); and TLR9 antagonist (ODN 2088, 1 μM, InvivoGen, catalog tlr-2088) or a control nucleotide (ODN 2088 control, InvivoGen, catalog tlrh-2088c) for 8 hours, followed by treatment with HMGB1.

Study approval. All animal procedures were performed with the approval of the IACUC of Columbia University and were in accordance with the Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011).

Statistics. All data are expressed as the mean ± SEM. An unpaired, 2-tailed t test was used for comparisons of 2 groups.

Author contributions

CH designed and performed in vivo experiments on liver injury and hepatocarcinogenesis and in vitro experiments, analyzed data, and wrote the manuscript. PH designed and performed in vivo experiments related to liver injury and hepatocarcinogenesis and analyzed data. JFP performed in vivo experiments related to hepatocarcinogenesis. RAF analyzed RNA-seq data and performed bioinformatics analysis. DJA coordinated HMGB1 bioanalysis and recombinant HMGB1 production. RFS conceptualized and oversaw all aspects of the study, designed experiments, analyzed data, and wrote the manuscript.

Acknowledgments

We would like to thank Geum Youn Gwak (Sungkyunkwan University School of Medicine, Seoul, Korea), who contributed to the generation of Hmgb1Δ/Δ mice; George Yeoh (University of Western Australia); Bin Gao (NIH, Bethesda, Maryland, USA) for providing BMOL cells; and Valentina Factor (NIH) for providing the A6 antibody. This study was supported by funding from the NIH (RO1CA200597, 1R01DK116620, and U01AA021912, to RFS), 5P30CA013696 (Columbia University Cancer Center support grant), and a fellowship from the German Research Foundation (Hu 1953/1-1).

Address correspondence to: Robert F. Schwabe, 1130 St. Nicholas Avenue, ICRC, Room 926, New York, New York 10032, USA. Phone: 212.851.5462; Email: rfs2102@cumc.columbia.edu.


The journal of Clinical Investigation